A finalized phase II report of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with peritoneal mesothelioma (PM).

被引：0
|
作者：
Simon, G. R.
Janne, P. A.
Langer, C.
Clarie, V.
Dowlati, A.
Gadgeel, S. M.
Kelly, K.
Ye, Z.
Obasaju, C. K.
Hood, K. E.
Kindler, H. L.
机构：
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[4] Univ New Mexico, Canc Res & Canc, Albuquerque, NM 87131 USA
[5] Case Western Reserve Univ, Cleveland, OH 44106 USA
[6] Wayne State Univ, Detroit, MI 48202 USA
[7] Univ Colorado, Hlth Sci Ctr, Aurora, CO USA
[8] Eli Lilly & Co, Indianapolis, IN 46285 USA
[9] Univ Chicago, Chicago, IL 60637 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：91S / 91S
页数：1
相关论文
共 50 条
  • [21] Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy
    Gouji Toyokawa
    Mitsuhiro Takenoyama
    Fumihiko Hirai
    Ryo Toyozawa
    Eiko Inamasu
    Miyako Kojo
    Yosuke Morodomi
    Yoshimasa Shiraishi
    Tomoyoshi Takenaka
    Masafumi Yamaguchi
    Mototsugu Shimokawa
    Takashi Seto
    Yukito Ichinose
    International Journal of Clinical Oncology, 2014, 19 : 601 - 606
  • [22] Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy
    Toyokawa, Gouji
    Takenoyama, Mitsuhiro
    Hirai, Fumihiko
    Toyozawa, Ryo
    Inamasu, Eiko
    Kojo, Miyako
    Morodomi, Yosuke
    Shiraishi, Yoshimasa
    Takenaka, Tomoyoshi
    Yamaguchi, Masafumi
    Shimokawa, Mototsugu
    Seto, Takashi
    Ichinose, Yukito
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (04) : 601 - 606
  • [23] Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma
    Nagata, Yusuke
    Sawada, Ryoichi
    Takashima, Atsuo
    Shoji, Hirokazu
    Honma, Yoshitaka
    Iwasa, Satoru
    Amano, Katsushi
    Kato, Ken
    Hamaguchi, Tetsuya
    Shimada, Yasuhiro
    Saruta, Masayuki
    Boku, Narikazu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (11) : 1004 - 1008
  • [24] Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: A multicenter phase II study
    Mavroudis, D
    Malamos, N
    Polyzos, A
    Kouroussis, C
    Christophilakis, C
    Varthalitis, I
    Androulakis, N
    Kalbakis, K
    Milaki, G
    Georgoulias, V
    ONCOLOGY, 2004, 67 (3-4) : 250 - 256
  • [25] Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma
    Scagliotti, GV
    Shin, DM
    Kindler, HL
    Vasconcelles, MJ
    Keppler, U
    Manegold, C
    Burris, H
    Gatzemeier, U
    Blatter, J
    Symanowski, JT
    Rusthoven, JJ
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) : 1556 - 1561
  • [26] CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas
    Jong Gwang Kim
    Sang Kyun Sohn
    Yee Soo Chae
    Dong Hwan Kim
    Jin Ho Baek
    Kyu Bo Lee
    Je-Jung Lee
    Ik-Joo Chung
    Hyeoung-Joon Kim
    Deok-Hwan Yang
    Won-Sik Lee
    Young-Don Joo
    Chang-Hak Sohn
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 35 - 39
  • [27] CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas
    Kim, JG
    Sohn, SK
    Chae, YS
    Kim, DH
    Baek, JH
    Lee, KB
    Lee, JJ
    Chung, IJ
    Kim, HJ
    Yang, DH
    Lee, WS
    Joo, YD
    Sohn, CH
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (01) : 35 - 39
  • [28] Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site - Reply
    Culine, S
    CANCER, 2004, 101 (03) : 654 - 655
  • [29] The effect of front-line chemotherapy on overall survival in patients with malignant pleural mesothelioma.
    Elkiran, Emin Tamer
    Sevinc, Alper
    Harputluoglu, Hakan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [30] Phase II randomized trial of single-agent pemetrexed or sequentially administered pemetrexed/gemcitabine as front-line chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) in elderly patients or patients ineligible for platinum-based chemotherapy
    Gridelli, C
    Reck, M
    Gregorc, V
    Migliorino, M
    Favaretto, A
    Schmittel, A
    Caffo, O
    Blatter, J
    Munoz, M
    Crucitta, E
    Rossi, A
    Koschel, G
    LUNG CANCER, 2005, 49 : S245 - S245
12345